Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.
Most study participants achieved viral suppression with minimal changes in kidney function or bone density.
Most people who stopped long-term nucleoside/nucleotide analogs did not need to restart treatment.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.
New research shows that treating these viruses can reduce liver cancer risk.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.